Ftse Mib
36.200,72
0,24%
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
NASDAQ
19.954,30
-0,50%
Bitcoin
104.389,73
-0,33%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Fate Therapeutics Inc (FATE) Fate Therapeutics Inc (FATE) Notizie

Fate Therapeutics Inc

FATE
1,33
-0,01 (-0,75%)
25 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/1/202500:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202500:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202500:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/1/202522:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/1/202522:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/1/202522:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202521:20EDGAR2Form 144 - Report of proposed sale of securities
10/1/202521:12EDGAR2Form 144 - Report of proposed sale of securities
10/1/202521:12EDGAR2Form 144 - Report of proposed sale of securities
06/1/202522:01EDGAR2Form 8-K - Current report
03/1/202522:01GLOBEFate Therapeutics Reports New Employee Inducement Awards..
09/12/202422:01GLOBEFate Therapeutics Presents New Phase 1 Clinical Data of..
03/12/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Award..
29/11/202420:33EDGAR2Form 8-K - Current report
29/11/202419:05GLOBEFate Therapeutics Announces Leadership Transition
26/11/202422:01GLOBEFate Therapeutics to Present at Upcoming December Investor..
18/11/202414:05GLOBEFate Therapeutics Presents 6-Month Follow-up Data on First..
18/11/202414:00GLOBEFate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed..
15/11/202401:50EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202422:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:01EDGAR2Form 8-K - Current report
12/11/202422:01GLOBEFate Therapeutics Reports Third Quarter 2024 Financial..
09/11/202419:30GLOBEFate Therapeutics Highlights Cancer-selective,..
08/11/202423:31EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
08/11/202422:01GLOBEFate Therapeutics Presents Pan-tumor Targeting Preclinical..
04/11/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Award..
26/10/202403:37EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
02/10/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Awards..
12/9/202422:01GLOBEFate Therapeutics to Present at 2024 Cantor Global..
30/8/202422:21EDGAR2Form 8-K - Current report
21/8/202422:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/8/202422:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202422:06EDGAR2Form 8-K - Current report
13/8/202422:05GLOBEFate Therapeutics Reports Second Quarter 2024 Financial..
07/8/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Awards..
01/8/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202423:59EDGAR2Form 3 - Initial statement of beneficial ownership of..
31/7/202422:03EDGAR2Form 8-K - Current report
31/7/202414:00GLOBEFate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR,..
02/7/202422:01GLOBEFate Therapeutics Reports New Employee Inducement Awards..
12/6/202400:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/6/202423:05EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/6/202422:31EDGAR2Form 8-K - Current report
07/6/202423:26EDGAR2Form 8-K - Current report
Apertura: 1,32 Min: 1,29 Max: 1,35
Chiusura: 1,34

La tua Cronologia

NASDAQ
FATE
Fate Therapeutics
NASDAQ
MRKR
Marker Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network